Th1Th2 and Tc1Tc2 T Cell Subsets in Transplantation Therapy
移植治疗中的 Th1Th2 和 Tc1Tc2 T 细胞亚群
基本信息
- 批准号:7969823
- 负责人:
- 金额:$ 65.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Acute Graft Versus Host DiseaseAddressAllogenicAllograftingBone Marrow TransplantationCancer PatientCell TherapyCellsClinicClinicalClinical ProtocolsClinical TrialsDataDoseDysmyelopoietic SyndromesElderlyEngineeringEngraftmentFamilyGraft RejectionGraft-Versus-Tumor InductionHematologic NeoplasmsHematopoietic Stem Cell TransplantationHematopoietic stem cellsHumanImmuneImpairmentIndividualInfectionInfusion proceduresLaboratoriesMarrowMediatingMedicalMetastatic Renal Cell CancerMethodologyMethodsModelingMultiple MyelomaMusNew JerseyOrganPatientsPharmaceutical PreparationsPrior ChemotherapyProtocols documentationReactionRefractoryResearchSirolimusSiteT-LymphocyteT-Lymphocyte SubsetsTh2 CellsTimeTranslatingTransplantationUnited States National Institutes of HealthUniversitiescancer therapycell typechemotherapydesigngraft vs host diseaseimmunoregulationin vivoleukemia/lymphomamouse modelnovel strategiespreventprogramsresponse
项目摘要
Allogeneic hematopoietic stem cell transplantation, often referred to as "bone marrow transplantation", represents a curative therapy for many individuals with leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome. However, the broadened application of transplantation therapy of these cancers is limited by two immune reactions that are mediated primarily by T cells, namely graft-versus-host disease (GVHD; T cell attack of donor cells against the patient) and graft rejection (or the host-versus-graft response; HVGR). GVHD is the main cause of lethality after transplantation. The HVGR results in the need to administer toxic doses of chemotherapy prior to transplanation, and thereby results in the current limitation of transplantation to individuals having a closely matched donor either from within the family or through the National Marrow Donor Program. Our laboratory focuses on new T cell graft engineering strategies designed to prevent GVHD and graft rejection. In murine models, we have shown that donor Th2 cells, which are generated ex vivo in the presence of the immune modulation drug rapamycin, can potently inhibit GVHD while preserving a component of the beneficial graft-versus-tumor (GVT) effect; furthermore, such Th2 cells effectively prevent the rejection of fully genetically mis-matched hematopoietic stem cells. We have made significant progress in translating these findings to the clinic. We have developed a method for generating human Th2 cells in rapamycin, and we have initiated a clinical trial investigating these cells in patients with refractory hematologic malignancy. Current data are consistent with our murine data, as recipients of Th2 cells grown in rapamycin have a low rate of acute GVHD; furthermore, administration of Th2 cells has allowed for a significant reduction in the amount of preparative chemotherapy required to achieve engraftment of the allograft. Such allogeneic Th2 cells are currently being evaluated on two clinical protocols. In the first protocol, NIH Clinical Center Protocol #04-C-0055, patients with refractory hematologic malignancy such as leukemia, lymphoma, and multiple myeloma are receiving a low-intensity transplant that is supplemented with donor Th2 cells; currently, approximately 100 patients have received therapy on this protocol. In the second protocol, NIH Clinical Center Protocol #08-C-0088, patients with refractory and metastatic renal cell carcinoma are receiving a low-intensity transplant that is supplemented with multiple infusions of donor Th2 cells. Of note, both of these protocols are being implemented in a multi-center manner, with Hackensack University in New Jersey serving as the multi-center site.
异基因造血干细胞移植,通常被称为"骨髓 移植"代表了许多患有白血病,淋巴瘤, 多发性骨髓瘤和骨髓增生异常综合征。然而,扩大应用 这些癌症的移植治疗受到两种介导的免疫反应的限制 主要通过T细胞,即移植物抗宿主病(GVHD; T细胞攻击供体细胞 抗患者)和移植物排斥(或宿主抗移植物反应; HVGR)。gvhd是 移植后死亡的主要原因。HVGR导致需要给药 在移植前使用毒性剂量的化疗,从而导致目前的 限制移植到具有密切匹配的供体的个体, 或者通过国家骨髓捐赠计划。我们的实验室专注于新的T细胞 旨在预防GVHD和移植排斥的移植工程策略。在鼠模型中, 我们已经证明,在免疫原存在下离体产生的供体Th2细胞, 调节药物雷帕霉素可以有效抑制GVHD,同时保留GVHD的一种成分。 有益的移植物抗肿瘤(GVT)效应;此外,这种Th2细胞有效地预防 排斥基因完全不匹配的造血干细胞。我们取得了 在将这些发现转化为临床方面取得了重大进展。我们已经开发出一种方法 在雷帕霉素中产生人类Th2细胞,我们已经开始了一项临床试验, 在难治性恶性血液病患者中研究这些细胞。电流数据 与我们的小鼠数据一致,因为在雷帕霉素中生长的Th2细胞的受体具有低的比率, 急性GVHD;此外,Th2细胞的施用允许显著的 减少了实现移植物植入所需的准备性化疗的量, 同种异体移植这种同种异体Th2细胞目前正在两个临床方案中进行评估。 在第一个方案中,NIH临床中心方案#04-C-0055,难治性 血液恶性肿瘤如白血病、淋巴瘤和多发性骨髓瘤正在接受 补充供体Th2细胞的低强度移植;目前,大约 100名患者接受了该方案的治疗。在第二个方案中,NIH临床 中心方案#08-C-0088,难治性和转移性肾细胞癌患者 接受补充有供体Th2的多次输注的低强度移植 细胞值得注意的是,这两个协议都是以多中心的方式实施的, 位于新泽西的哈肯萨克大学作为多中心研究中心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL FOWLER其他文献
DANIEL FOWLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL FOWLER', 18)}}的其他基金
AUTOLOGOUS AND ALLOGENEIC T CELL STRATEGIES FOR HEMA C MALIGNANCY
HEMA C 恶性肿瘤的自体和同种异体 T 细胞策略
- 批准号:
6123770 - 财政年份:
- 资助金额:
$ 65.13万 - 项目类别:
Autologous and Allogeneic T Cell Strategies for the Treatment of Hematologic Mal
治疗血液病的自体和同种异体 T 细胞策略
- 批准号:
6433441 - 财政年份:
- 资助金额:
$ 65.13万 - 项目类别:
Th1Th2 and Tc1Tc2 T Cell Subsets in Transplantation Therapy
移植治疗中的 Th1Th2 和 Tc1Tc2 T 细胞亚群
- 批准号:
9154270 - 财政年份:
- 资助金额:
$ 65.13万 - 项目类别:
Th1/Th2 and Tc1/Tc2 T Cell Subsets in Transplantation Th
移植中的 Th1/Th2 和 Tc1/Tc2 T 细胞亚群
- 批准号:
6948127 - 财政年份:
- 资助金额:
$ 65.13万 - 项目类别:
Th1/Th2 and Tc1/Tc2 T Cell Subsets in Transplantation
移植中的 Th1/Th2 和 Tc1/Tc2 T 细胞亚群
- 批准号:
7068937 - 财政年份:
- 资助金额:
$ 65.13万 - 项目类别:
Th1Th2 and Tc1Tc2 T Cell Subsets in Transplantation Therapy
移植治疗中的 Th1Th2 和 Tc1Tc2 T 细胞亚群
- 批准号:
8554042 - 财政年份:
- 资助金额:
$ 65.13万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 65.13万 - 项目类别:
Research Grant